Trial Profile
Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 16 Mar 2023 Status changed from recruiting to discontinued.
- 06 Jan 2011 New trial record